Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

by Kinjel Shah

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Zacks Equity Research

Company News for Jul 9, 2025

by Zacks Equity Research

Companies in The News Are: FCX, MRNA, NRG, HES

Zacks Equity Research

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

by Zacks Equity Research

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Zacks Equity Research

Moderna Stock Gains on Encouraging Flu Vaccine Data

by Zacks Equity Research

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Zacks Equity Research

Company News for Jul 1, 2025

by Zacks Equity Research

Companies In The News Are: META, MRNA, HOOD, AAPL.

Kinjel Shah headshot

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

by Kinjel Shah

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.

Zacks Equity Research

Moderna (MRNA) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.

Kinjel Shah headshot

Merck Moves Past 50-Day Average: How to Play MRK Stock Now

by Kinjel Shah

MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.

Zacks Equity Research

Moderna (MRNA) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.

Zacks Equity Research

EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy

by Zacks Equity Research

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.